Triazolam and melatonin effects on cardiac autonomic function during sleep

Area of Science:

• Cardiology
• Sleep Medicine
• Pharmacology

Background:

• Benzodiazepine (BDZ) administration is known to decrease cardiac vagal tone during wakefulness.
• Limited data exist on the effects of BDZs and melatonin on cardiac autonomic function during sleep.
• Melatonin (MLT) has shown potential to increase vagal tone in animal studies.

Purpose of the Study:

• To evaluate heart rate (HR) variability during sleep following a single bedtime dose of triazolam (TRI) and melatonin (MLT).
• To assess tonic (vagal) and phasic (sympathetic) HR modifications during sleep stages (REM and NREM).

Main Methods:

• A randomized, placebo-controlled study involving six healthy young subjects.
• Administration of triazolam (0.125 mg), melatonin (100 mg), or placebo at bedtime.
• Analysis of heart rate variability parameters during sleep, including sympathetic and vagal activity.

Main Results:

• No significant changes in sympathetic activity were observed with triazolam or melatonin compared to placebo.
• Triazolam administration resulted in a significant decrease in vagal tone during sleep.
• Melatonin did not significantly alter vagal tone during sleep.

Conclusions:

• Triazolam, a benzodiazepine, reduces cardiac vagal tone during sleep in healthy young adults.
• These findings align with previous research indicating a decrease in vagal tone associated with benzodiazepine use.
• Melatonin does not appear to affect cardiac autonomic function, specifically vagal tone, during sleep in this context.